Profil Institut für Stoffwechselforschung GmbH clinical trials
The registry lists 26 studies whose lead sponsor is Profil Institut für Stoffwechselforschung GmbH. 1 is recruiting or about to start. Per ClinicalTrials.gov, last updated Nov 3, 2026.
Our grouping of 1 registry name, not the registry’s. See them and correct one ↓
- 26studies on the registry
- 1open to participants now
Get an email when these change. Save the Profil Institut für Stoffwechselforschung GmbH studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
What it is testing
The drugs Profil Institut für Stoffwechselforschung GmbH’s studies test, most studies first; none is open now — 15 drugs with a page of their own. Each count opens the studies in search.
Studies, none open
- 0 open · 2
- 0 open · 2
- 0 open · 2
- 0 open · 1
- 0 open · 1
- 0 open · 1
- 0 open · 1
- 0 open · 1
- 0 open · 1
- 0 open · 1
Show 5 moreShow fewer
What changed recently
From the registry's own updates since Oct 20, 2026.
Newly registered1
All 26 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
Over the years
- 07
- 08
- 09
- 10
- 11
- 12
- 613
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 026
By the year each study started; 5 started before 2007. 2026 so far in the lighter column.
Registry sponsor names on this page
Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Profil Institut für Stoffwechselforschung GmbH.
- Profil Institut für Stoffwechselforschung GmbH26 studiesSame company
Something wrong?
Focus areas
Conditions Profil Institut für Stoffwechselforschung GmbH leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 26 of 26.
- Clinical Research Trial to Study Insulin Sensitivity Using Automated Glucose Clamp TechnologyNot yet recruitingNCT07913698
- Clinical Experimental Study to Investigate Specific Features of ClampArt®CompletedNCT01906970Not applicable
- Validation of the Doubly Labelled Water Method in Subjects With Type 2 Diabetes MellitusCompletedNCT02518581Not applicable
- Explorative Assessment of Biomarkers in Overweight and Obese SubjectsCompletedNCT01910051
- Sitagliptin and the Risk for Hypoglycaemia in Type 2 Diabetes PatientsCompletedNCT03359590Phase 2
- Empagliflozin and Sympathetic Nerve TrafficCompletedNCT03254849Phase 4
- Effects of Victoza® Versus Lyxumia® on Gastroesophageal Reflux, Gastric Emptying and Gastric Acid SecretionTerminatedNCT02231658Phase 1
- A Study to Investigate the Glucose Lowering Effects of Dextromethorphan Alone or in Combination With Sitagliptin in Subjects With Type 2 Diabetes Mellitus (T2DM) After an Oral Glucose Tolerance TestCompletedNCT01936025Phase 2
- An Exploratory Clinical Trial to Generate Whole Blood Samples for Analysing Genetic PolymorphismsWithdrawnNCT02057497
- DIATOR-Diabetes Intervention With AtorvastatinTerminatedNCT00974740Phase 1
- Effects of Linagliptin on Active GLP-1 Concentrations in Subjects With Renal ImpairmentCompletedNCT01903070Phase 4
- Effects of Linagliptin in Addition to Empagliflozin on Islet Cell PhysiologyCompletedNCT02401880Phase 4
- Impact of Combined of Lantus(Insulin Glargine) and Lyxumia (Lixisenatide) on Insulin Secretion and Gastric EmptyingCompletedNCT01910194Phase 2
- A Trial to Compare the PK and PD of Insulin Lispro Administered Into Different Tissues in Subjects With Diabetes Mellitus Type 1CompletedNCT02221323Phase 2
- A Trial Investigating the Influence of Injection Speed and Volume on the Perception of Subcutaneous Injection PainCompletedNCT01937702Phase 1
- Trial to Compare the Relative Pharmacodynamic Properties of Different Glucagon DosagesCompletedNCT01916265Phase 1
- A Trial Investigating the Accuracy and Precision of the BGStar® and iBGStar® Blood Glucose Meter in Subjects With Type 1 DiabetesCompletedNCT01730885Phase 4
- Dextromethorphan, Amantadine and Glucose Homeostasis in Diabetes SubjectsCompletedNCT01441986Phase 2
- Effects of Food Advanced Glycation Endproducts on Vascular Function in DiabetesCompletedNCT01456026Not applicable
- Performance Study Using the OptiScanner on Healthy DiabeticsCompletedNCT01135771Phase 1
- Glucose Clamp Study to Prove Hypo- and Hyperglycemic Episodes Using a Non-invasive Glucose Monitoring DeviceCompletedNCT01060917Phase 1/2
- Changes in Serum Electrolytes at Different Glucose Concentrations + Impact on a Non-invasive Glucose Monitoring MethodCompletedNCT01058577Phase 1
- Oral Insulin: A Comparison With Subcutaneous Regular Human Insulin in Patients With Type 2 DiabetesCompletedNCT00982254Phase 1
- Adjunctive Therapy of Exenatide or Sitagliptin to Insulin Glargine in Type 2 DiabetesCompletedNCT00971659Phase 1
- Expanded PK and PD of Insulin Glulisine Versus Insulin Aspart in Healthy VolunteersCompletedNCT00969592Phase 1
- Metabolic Effect of Insulin Aspart and Human Insulin in Different DosesCompletedNCT00513643Phase 1